Biosimilars Market by Product (Monoclonal antibodies (infliximab, rituximab, trastuzumab), Insulin, Interferon, Etanercept, Glucagon, Calcitonin), Indication (Oncology, Chronic Disease, Blood Disorder, Autoimmune Disease), Region – Global Forecast to 2026

Biosimilars Market by Product (Monoclonal antibodies (infliximab, rituximab, trastuzumab), Insulin, Interferon, Etanercept, Glucagon, Calcitonin), Indication (Oncology, Chronic Disease, Blood Disorder, Autoimmune Disease), Region – Global Forecast to 2026

The global biosimilars market is projected to reach USD 44.7 billion by 2026 from USD 15.6 billion in 2021, at a CAGR of 23.5% during the forecast period of 2021 to 2026. Market growth is largely driven by the rising incidence of chronic diseases and increasing demand of biosimilars for their cost-effectiveness. Regulatory approvals and other regulations favouring biosimilars adoption in different countries is also a major driving factor in the biosimilars market. However, the complexities in the development and manufacturing of biosimilars and resistance from reference biologic manufacturers is expected to restrain the growth of this market during the forecast period.

“The monoclonal antibodies productsegment accounted for the highest growth rate in the biosimilarsmarket, byproduct, during the forecast period”

In 2020, the monoclonal antibodies product segment accounted for the largest share (27.5%) of the biosimilars market, mainly due to the low prices of biosimilar monoclonal antibodies compared to the reference drugs and their wide use in the treatment of cancer, autoimmune disorders, and osteoporosis. They are also used in indications such as rheumatoid arthritis, multiple sclerosis, and macular degeneration. The growth of the fastest-growing segment was attributed to the rising incidence of cancer cases and chronic diseases and growth in the geriatric population.

“Oncologysegment accounted for the largest share of the indication segment”

Based on the indication, the biosimilars market is segmented into oncology, inflammatory and autoimmune diseases, chronic diseases, blood disorders, growth hormone deficiency, infectious diseases, and other indications (infertility, hypoglycemia, myocardial infarction, postmenopausal osteoporosis, chronic kidney failure, and ophthalmic diseases). Oncology is the largest segment in this market owing to the availability of biosimilars at a lower price than innovative biologics and a large number of cancer patients. The availability of biosimilars in the field of oncology has lowered prices and made cancer treatment more affordable and accessible. Also, due to the high incidence and prevalence of cancer, healthcare systems across the globe are focusing on reducing the burden of cancer by adopting cost effective treatment options. In this scenario, biosimilar drugs might witness widespread adoption in major markets such as the US, Europe, and the Asia Pacific. Considering these factors and the upending competition from biosimilars, many major biologic pharmaceutical companies are making significant investments in the development and approval of biosimilar drugs.

“Asia Pacific: The fastest-growing regionin thebiosimilarsmarket”

Thebiosimilarsmarket is segmented into Europe, Asia Pacific, North America, latin America and Middle East and Africa. The APAC market, on the other hand, is expected to be the fastest-growing regional segment during the forecast period due to the presence of many emerging players, less-stringent regulations, and increasing cooperation among leading and regional players for development, manufacture and commercialization of biosimilars.

The primary interviews conducted for this report can be categorized as follows:
By Respondent: Supply Side- 80%and Demand Side 20%
By Designation: Managers - 55%, CXOs - 20%, and Executives - 25%
By Region: North America -50%, Europe -20%, Asia-Pacific -20%, RoW -10%

Lists of Companies Profiled in the Report:
Novartis AG (Switzerland)
Pfizer, Inc. (US)
Dr. Reddy’s Laboratories Ltd (India)
Amgen, Inc. (US)
Eli Lilly and Company (US)
Teva Pharmaceutical Industries Ltd. (Israel)
Fresenius SE & Co. KGaA (Germany)
STADA Arzneimittel AG (Germany)
Boehringer Ingelheim (Germany)
Gedeon Richter PLC (Hungary)
Celltrion (South Korea)
Samsung Biologics (South Korea)
CoherusBioSciences (US)
Biocon Limited (India)
Viatris, Inc. (US)
Amega Biotech (Argentina)
Apotex, Inc. (Canada)
Biocad (Russia)
mAbxience (Spain)
Probiomed S.A. De C.V. (Mexico)
Fujifilm Kyowa Kirin Biologics Co., Ltd. (Japan)
Intas Pharmaceuticals Ltd. (India)
Theramex (UK)
Reliance Life Sciences (India)
Kashiv Biosciences (US)

Research Coverage:

This report provides a detailed picture of thebiosimilars market. It aims at estimating the size and future growth potential of the market across different segments such as theproduct,indication and region. The report also includes an in-depth competitive analysis ofthe key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall biosimilars marketand its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers,restraints,trends,challengesand opportunities.


  • INTRODUCTION
    • OBJECTIVES OF THE STUDY
    • MARKET DEFINITION
      • INCLUSIONS & EXCLUSIONS OF THE STUDY
        • Table BIOSIMILARS MARKET: INCLUSIONS & EXCLUSIONS
    • MARKET SCOPE
      • MARKETS COVERED
      • YEARS CONSIDERED FOR THE STUDY
    • CURRENCY
    • STAKEHOLDERS
    • LIMITATIONS
    • SUMMARY OF CHANGES
  • RESEARCH METHODOLOGY
    • RESEARCH APPROACH
    • SECONDARY DATA
    • PRIMARY DATA
    • MARKET BREAKDOWN AND DATA TRIANGULATION
    • MARKET ESTIMATION METHODOLOGY
      • BOTTOM-UP APPROACH
      • TOP-DOWN APPROACH
    • GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
    • INSIGHTS FROM PRIMARIES
    • RESEARCH ASSUMPTIONS
    • LIMITATIONS
    • RISK ASSESSMENT
  • EXECUTIVE SUMMARY
  • PREMIUM INSIGHTS
    • BIOSIMILARS MARKET OVERVIEW
    • NORTH AMERICA: BIOSIMILARS MARKET, BY PRODUCT AND COUNTRY (2020)
    • GEOGRAPHICAL SNAPSHOT OF THE BIOSIMILARS MARKET
  • MARKET OVERVIEW
    • INTRODUCTION
    • MARKET DYNAMICS
      • DRIVERS
      • RESTRAINTS
      • OPPORTUNITIES
        • Table LIST OF KEY BIOLOGICS UNDER THE THREAT OF PATENT EXPIRY
      • CHALLENGES
      • TRENDS
        • Table MAJOR COLLABORATIONS IN THE BIOSIMILARS MARKET (2017–2020)
    • COVID-19 IMPACT ANALYSIS
    • TECHNOLOGY ANALYSIS
      • Table COMPARISON OF ORIGINAL BIOLOGICS WITH BIOSIMILARS
      • Table GENERIC DRUGS VS. BIOSIMILARS
    • VALUE CHAIN ANALYSIS
    • ECOSYSTEM MARKET MAP
    • SUPPLY CHAIN ANALYSIS
    • PORTER'S FIVE FORCES ANALYSIS
      • Table PORTER'S FIVE FORCES: IMPACT ANALYSIS ON THE BIOSIMILARS MARKET
      • THREAT FROM NEW ENTRANTS
      • THREAT FROM SUBSTITUTES
      • BARGAINING POWER OF SUPPLIERS
      • BARGAINING POWER OF BUYERS
      • INTENSITY OF COMPETITION RIVALRY
    • REGULATORY LANDSCAPE
      • Table REGULATORY LANDSCAPE FOR THE BIOSIMILARS MARKET
  • BIOSIMILARS MARKET, BY PRODUCT
    • INTRODUCTION
      • Table BIOSIMILARS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
    • MONOCLONAL ANTIBODIES
      • Table BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
      • Table BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2019–2026 (USD MILLION)
      • INFLIXIMAB
        • Table BIOSIMILARS MARKET FOR INFLIXIMAB, BY REGION, 2019–2026 (USD MILLION)
      • TRASTUZUMAB
        • Table BIOSIMILARS MARKET FOR TRASTUZUMAB, BY REGION, 2019–2026 (USD MILLION)
      • RITUXIMAB
        • Table BIOSIMILARS MARKET FOR RITUXIMAB, BY REGION, 2019–2026 (USD MILLION)
      • ADALIMUMAB
        • Table BIOSIMILARS MARKET FOR ADALIMUMAB, BY REGION, 2019–2026 (USD MILLION)
      • OTHER MONOCLONAL ANTIBODIES
        • Table BIOSIMILARS MARKET FOR OTHER MONOCLONAL ANTIBODIES, BY REGION, 2019–2026 (USD MILLION)
    • INSULIN
      • INCREASING INCIDENCE OF DIABETES TO SUPPORT MARKET GROWTH
        • Table BIOSIMILARS MARKET FOR INSULIN, BY REGION, 2019–2026 (USD MILLION)
    • GRANULOCYTE COLONY-STIMULATING FACTOR
      • G-CSF IS USED TO TREAT CANCER PATIENTS WITH NEUTROPENIA OCCURRING AFTER CHEMOTHERAPY
        • Table LIST OF APPROVED BIOSIMILARS FOR G-CSF
        • Table BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY REGION, 2019–2026 (USD MILLION)
    • ERYTHROPOIETIN
      • RISING INCIDENCE OF BLOOD DISORDERS WILL DRIVE MARKET GROWTH
        • Table LIST OF APPROVED BIOSIMILARS FOR ERYTHROPOIETIN
        • Table BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY REGION, 2019–2026 (USD MILLION)
    • RECOMBINANT HUMAN GROWTH HORMONE
      • MARKET GROWTH IS DRIVEN PRIMARILY BY THE INCREASING INCIDENCE OF GROWTH DEFICIENCY DISORDERS
        • Table BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY REGION, 2019–2026 (USD MILLION)
    • ETANERCEPT
      • APAC TO WITNESS THE HIGHEST GROWTH IN THE ETANERCEPT MARKET DURING THE FORECAST PERIOD
        • Table BIOSIMILARS MARKET FOR ETANERCEPT, BY REGION, 2019–2026 (USD MILLION)
    • FOLLITROPIN
      • INCREASING APPLICATION OF FOLLITROPIN IN INFERTILITY TREATMENT TO DRIVE MARKET GROWTH
        • Table BIOSIMILARS MARKET FOR FOLLITROPIN, BY REGION, 2019–2026 (USD MILLION)
    • TERIPARATIDE
      • INCREASING INCIDENCE OF OSTEOPOROSIS IS THE MAJOR FACTOR DRIVING MARKET GROWTH
        • Table BIOSIMILARS MARKET FOR TERIPARATIDE, BY REGION, 2019–2026 (USD MILLION)
    • INTERFERONS
      • RISING INCIDENCE OF INFECTIOUS DISEASES TO SUPPORT MARKET GROWTH
        • Table BIOSIMILARS MARKET FOR INTERFERONS, BY REGION, 2019–2026 (USD MILLION)
    • ENOXAPARIN SODIUM
      • WIDE RANGE OF APPLICATIONS HAVE SUPPORTED THE DEMAND FOR ENOXAPARIN SODIUM BIOSIMILARS
        • Table BIOSIMILARS MARKET FOR ENOXAPARIN SODIUM, BY REGION, 2019–2026 (USD MILLION)
    • GLUCAGON
      • SANDOZ IS A MAJOR PLAYER IN THE GLUCAGON BIOSIMILARS MARKET
        • Table BIOSIMILARS MARKET FOR GLUCAGON, BY REGION, 2019–2026 (USD MILLION)
    • CALCITONIN
      • INCREASING INCIDENCE OF OSTEOPOROSIS TO DRIVE MARKET GROWTH
        • Table BIOSIMILARS MARKET FOR CALCITONIN, BY REGION, 2019–2026 (USD MILLION)
  • BIOSIMILARS MARKET, BY INDICATION
    • INTRODUCTION
      • Table BIOSIMILARS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
    • ONCOLOGY
      • RISING BURDEN OF CANCER TO DRIVE THE DEMAND FOR BIOSIMILARS
        • Table BIOSIMILARS APPROVED BY THE US FDA FOR ONCOLOGICAL INDICATIONS, 2018-2020
        • Table BIOSIMILARS MARKET FOR ONCOLOGY, BY REGION, 2019–2026 (USD MILLION)
    • INFLAMMATORY & AUTOIMMUNE DISEASES
      • CHANGES IN LIFESTYLE AND ENVIRONMENTAL CONDITIONS HAVE INCREASED THE INCIDENCE OF INFLAMMATORY & AUTOIMMUNE DISEASES
        • Table BIOSIMILARS MARKET FOR INFLAMMATORY AND AUTOIMMUNE DISEASES, BY REGION, 2019–2026 (USD MILLION)
    • CHRONIC DISEASES
      • HIGH BURDEN OF CVD & DIABETES WORLDWIDE TO DRIVE MARKET GROWTH
        • Table BIOSIMILARS APPROVED BY THE US FDA FOR CHRONIC DISEASES, 2018–2020
        • Table BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY REGION, 2019–2026 (USD MILLION)
    • BLOOD DISORDERS
      • INCREASING INCIDENCE OF BLOOD DISORDERS HAS INCREASED THE DEMAND FOR BIOSIMILARS FOR THIS INDICATION SEGMENT
        • Table BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY REGION, 2019–2026 (USD MILLION)
    • GROWTH HORMONE DEFICIENCY
      • GROWING USE OF BIOSIMILARS FOR THE TREATMENT OF THIS MEDICAL CONDITION TO SUPPORT MARKET GROWTH
        • Table BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY, BY REGION, 2019–2026 (USD MILLION)
    • INFECTIOUS DISEASES
      • BIOSIMILARS MARKET FOR INFECTIOUS DISEASES IS EXPECTED TO BE THE HIGHEST IN THE ASIA PACIFIC
        • Table BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2019–2026 (USD MILLION)
    • OTHER INDICATIONS
      • Table BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY REGION, 2019–2026 (USD MILLION)
  • BIOSIMILARS MARKET, BY REGION
    • INTRODUCTION
      • Table BIOSIMILARS MARKET, BY REGION, 2019–2026 (USD MILLION)
    • EUROPE
      • Table LIST OF BIOSIMILARS APPROVED IN EUROPE
      • Table EUROPE: BIOSIMILARS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
      • Table EUROPE: BIOSIMILARS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
      • Table EUROPE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
      • Table EUROPE: BIOSIMILARS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
      • UK
        • Table LIST OF BIOSIMILARS IN THE UK
        • Table UK: BIOSIMILARS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
        • Table UK: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
        • Table UK: BIOSIMILARS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
      • FRANCE
        • Table FRANCE: BIOSIMILARS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
        • Table FRANCE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
        • Table FRANCE: BIOSIMILARS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
      • GERMANY
        • Table GERMANY: BIOSIMILARS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
        • Table GERMANY: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
        • Table GERMANY: BIOSIMILARS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
      • ITALY
        • Table ITALY: BIOSIMILARS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
        • Table ITALY: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
        • Table ITALY: BIOSIMILARS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
      • SPAIN
        • Table SPAIN: BIOSIMILARS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
        • Table SPAIN: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
        • Table SPAIN: BIOSIMILARS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
      • REST OF EUROPE
        • Table ROE: BIOSIMILARS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
        • Table ROE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
        • Table ROE: BIOSIMILARS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
    • ASIA PACIFIC
      • Table ASIA PACIFIC: BIOSIMILARS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
      • Table ASIA PACIFIC: BIOSIMILARS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
      • Table ASIA PACIFIC: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
      • Table ASIA PACIFIC: BIOSIMILARS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
      • INDIA
        • Table BIOSIMILARS APPROVED AND MARKETED IN INDIA
        • Table INDIA: BIOSIMILARS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
        • Table INDIA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
        • Table INDIA: BIOSIMILARS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
      • CHINA
        • Table BIOSIMILARS APPROVED IN CHINA
        • Table CHINA: BIOSIMILARS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
        • Table CHINA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
        • Table CHINA: BIOSIMILARS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
      • SOUTH KOREA
        • Table LIST OF BIOSIMILARS APPROVED IN SOUTH KOREA
        • Table SOUTH KOREA: BIOSIMILARS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
        • Table SOUTH KOREA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
        • Table SOUTH KOREA: BIOSIMILARS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
      • JAPAN
        • Table LIST OF BIOSIMILARS APPROVED IN JAPAN
        • Table JAPAN: BIOSIMILARS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
        • Table JAPAN: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
        • Table JAPAN: BIOSIMILARS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
      • AUSTRALIA
        • Table LIST OF BIOSIMILARS APPROVED IN AUSTRALIA
        • Table AUSTRALIA: BIOSIMILARS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
        • Table AUSTRALIA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
        • Table AUSTRALIA: BIOSIMILARS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
      • REST OF ASIA PACIFIC
        • Table LIST OF BIOSIMILARS APPROVED IN NEW ZEALAND
        • Table LIST OF BIOSIMILARS APPROVED IN MALAYSIA
        • Table LIST OF BIOSIMILARS APPROVED IN SINGAPORE
        • Table ROAPAC: BIOSIMILARS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
        • Table ROAPAC: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
        • Table ROAPAC: BIOSIMILARS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
    • NORTH AMERICA
      • Table NORTH AMERICA: BIOSIMILARS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
      • Table NORTH AMERICA: BIOSIMILARS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
      • Table NORTH AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
      • Table NORTH AMERICA: BIOSIMILARS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
      • US
        • Table LIST OF BIOSIMILARS APPROVED IN THE US
        • Table US: BIOSIMILARS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
        • Table US: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
        • Table US: BIOSIMILARS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
      • CANADA
        • Table LIST OF BIOSIMILARS APPROVED IN CANADA
        • Table CANADA: BIOSIMILARS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
        • Table CANADA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
        • Table CANADA: BIOSIMILARS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
    • LATIN AMERICA
      • RISING INCIDENCE OF CANCER TO DRIVE MARKET GROWTH
        • Table LIST OF BIOSIMILARS APPROVED IN LATIN AMERICA
        • Table LATIN AMERICA: BIOSIMILARS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
        • Table LATIN AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
        • Table LATIN AMERICA: BIOSIMILARS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
    • MIDDLE EAST AND AFRICA
      • FAVORABLE REGULATORY REFORMS AND INFRASTRUCTURAL DEVELOPMENT TO FAVOR MARKET GROWTH
        • Table MIDDLE EAST AND AFRICA: BIOSIMILARS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
        • Table MIDDLE EAST AND AFRICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
        • Table MIDDLE EAST AND AFRICA: BIOSIMILARS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
  • COMPETITIVE LANDSCAPE
    • INTRODUCTION
    • RIGHT-TO-WIN APPROACH
    • REVENUE SHARE ANALYSIS OF KEY MARKET PLAYERS
    • MARKET SHARE ANALYSIS
    • COMPANY EVALUATION QUADRANT
      • STARS
      • EMERGING LEADERS
      • PERVASIVE PLAYERS
      • PARTICIPANTS
    • COMPANY EVALUATION QUADRANT: START-UPS/SMES
      • PROGRESSIVE COMPANIES
      • STARTING BLOCKS
      • RESPONSIVE COMPANIES
      • DYNAMIC COMPANIES
    • COMPETITIVE BENCHMARKING
      • COMPANY PRODUCT FOOTPRINT
      • COMPANY INDICATION FOOTPRINT
      • COMPANY REGIONAL FOOTPRINT
    • GROWTH STRATEGIES ADOPTED BY EMERGING AND KEY PLAYERS
      • PRODUCT LAUNCHES & APPROVALS
      • DEALS
      • OTHER DEVELOPMENTS
  • COMPANY PROFILES
    • MAJOR PLAYERS
      • NOVARTIS AG
        • Table NOVARTIS AG: BUSINESS OVERVIEW
      • PFIZER INC.
        • Table PFIZER INC: BUSINESS OVERVIEW
      • DR. REDDY'S LABORATORIES LTD.
        • Table DR. REDDY'S LABORATORIES: BUSINESS OVERVIEW
      • AMGEN INC.
        • Table AMGEN INC.: BUSINESS OVERVIEW
      • ELI LILLY AND COMPANY
        • Table ELI LILLY AND COMPANY: BUSINESS OVERVIEW
      • TEVA PHARMACEUTICAL INDUSTRIES LTD.
        • Table TEVA PHARMACEUTICAL INDUSTRIES LTD.: BUSINESS OVERVIEW
      • FRESENIUS SE & CO. KGAA
        • Table FRESENIUS SE & CO. KGAA: BUSINESS OVERVIEW
      • STADA ARZNEIMITTEL AG
        • Table STADA ARZNEIMITTEL: BUSINESS OVERVIEW
      • BOEHRINGER INGELHEIM
        • Table BOEHRINGER INGELHEIM: BUSINESS OVERVIEW
      • GEDEON RICHTER PLC
        • Table GEDEON RICHTER PLC: BUSINESS OVERVIEW
      • CELLTRION
        • Table CELLTRION: BUSINESS OVERVIEW
      • SAMSUNG BIOLOGICS
        • Table SAMSUNG BIOLOGICS: BUSINESS OVERVIEW
      • COHERUS BIOSCIENCES
        • Table COHERUS BIOSCIENCES: BUSINESS OVERVIEW
      • BIOCON LIMITED
        • Table BIOCON LIMITED: BUSINESS OVERVIEW
      • VIATRIS
        • Table VIATRIS: BUSINESS OVERVIEW
    • OTHER PLAYERS
      • AMEGA BIOTECH
        • Table AMEGA BIOTECH: BUSINESS OVERVIEW
      • APOTEX INC.
        • Table APOTEX INC.: BUSINESS OVERVIEW
      • BIOCAD
        • Table BIOCAD: BUSINESS OVERVIEW
      • MABXIENCE
        • Table MABXIENCE: BUSINESS OVERVIEW
      • PROBIOMED S.A. DE C.V.
        • Table PROBIOMED: BUSINESS OVERVIEW
      • FUJIFILM KYOWA KIRIN BIOLOGICS CO., LTD.
        • Table FUJIFILM KYOWA KIRIN BIOLOGICS: BUSINESS OVERVIEW
      • INTAS PHARMACEUTICALS LTD.
        • Table INTAS PHARMACEUTICALS LTD.: BUSINESS OVERVIEW
      • THERAMEX
        • Table THERAMEX: BUSINESS OVERVIEW
      • RELIANCE LIFE SCIENCES
        • Table RELIANCE LIFE SCIENCES: BUSINESS OVERVIEW
      • KASHIV BIOSCIENCES
        • Table KASHIV BIOSCIENCES: BUSINESS OVERVIEW
  • APPENDIX
    • DISCUSSION GUIDE
    • KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
    • AVAILABLE CUSTOMIZATIONS
    • RELATED REPORTS
    • AUTHOR DETAILS

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook